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ABSTRACT
The combinatorial control of gene expression by
the association of members of different families
of transcription factors is a common theme in
eukaryotic transcriptional control. The MADS-box
transcription factors SRF and Mcm1 represent
paradigms for such regulation through their
interaction with numerous partner proteins. For
example, in Saccharomyces cerevisiae, Mcm1 inter-
acts with the forkhead transcription factor Fkh2.
Here, we identify a novel interaction between SRF
and the Forkhead transcription factor FOXK1
in human cells. The importance of this interaction
is shown for the regulation of the SRF target
genes SM a-actin and PPGB. The binding of
FOXK1 to the SM a-actin and PPGB promoters
requires the presence of SRF on the promoter.
FOXK1 acts as a transcriptional repressor and it
represses SM a-actin and PPGB expression. Thus
FOXK1 represents an additional member of the
growing repertoire of transcription factors that can
interact with SRF and modulate the transcriptional
output from SRF-regulated promoters.
INTRODUCTION
The regulation of eukaryotic promoters is complex and
involves the combinatorial action of transcription factors
(1). These transcription factors often form distinct
modules which coregulate the expression of groups of
genes with related function. One example of such a
module, is the complex formed by the association of the
Forkhead transcription factor Fkh2p and the MADS-box
transcription factor Mcm1p in Saccharomyces cerevisiae.
This complex controls the cyclical activation of a cohort
of genes expressed during the late G2 and M phases of
the cell cycle (2–5). Mcm1p itself functions in a number of
alternative complexes with other coregulators to target
genes involved in diﬀerent biological processes (6,7).
Indeed, combinatorial interactions with other transcrip-
tion factors are typical of members of the MADS-box
transcription factor family, including the mammalian
protein SRF. Moreover, some of these combinatorial
interactions appear to be evolutionarily conserved as, for
example, both SRF and Mcm1p show interactions with
homeodomain transcription factors (8–11).
The yeast forkhead protein Fkh2p contains two deﬁned
domains, the Forkhead DNA-binding domain and the
phospho-peptide binding FHA domain. In Fkh2p, the
FHA domain acts as a transcriptional activation domain
that functions through phosphorylation-dependent
recruitment of the coactivator Ndd1p (12,13). There are
over 40 human Forkhead transcription factors (14).
However, only two of these are known to possess FHA
domains in addition to their Forkhead DNA-binding
domain, FOXK1 and FOXK2. The mouse version of
FOXK1, Foxk1/MNF exists as two isoforms, MNFa and
MNFb which diﬀer through alternative splicing leading to
the production of the C-terminally truncated MNFb
isoform (15). Foxk1/MNF has been implicated in the
correct functioning of myogenic stem cells (16), which is in
part due to proliferative defects caused by Foxk1/MNF
loss (17). Molecularly, MNFb has been shown to act as a
transcriptional repressor protein, but the role of MNFa is
unclear (15). Other forkhead proteins such as FOXM1
have been linked to controlling cell cycle-dependent
expression of genes expressed at the G2-M boundary
during the cell cycle (18), suggesting that Forkhead
proteins play a similar role in cell cycle control in yeast
and mammalian systems.
Mcm1p and SRF are highly related proteins, especially
within their DNA-binding domains, and this is reﬂected
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CArG boxes (7). Moreover, many of the protein–protein
interfaces are conserved, exempliﬁed by the observation
that the yeast Forkhead transcription factor Fkh2p can
form ternary DNA bound complexes with both Mcm1p
and SRF (19). Thus, we hypothesized that in an analogous
manner to the yeast Mcm1p-Fkh2p complex, human SRF
might also interact with a Forkhead transcription factor
to control gene expression. Here we demonstrate that
SRF interacts physically and functionally with FOXK1,
demonstrating the evolutionary conservation of this
transcription factor module.
MATERIALS AND METHODS
Plasmid constructs
The following plasmids were used in mammalian cell
transfections. The L8G5E1a-Luc and LexA-VP16
constructs were provided by C. Lemercier (20). pCH110
(Pharmacia), pEF1/myc-His/LacZ (Invitrogen), p6xFOX-
Luc (kindly provided by R. Costa; 21), p5xCArG-Luc
(Stratagene), pGL3-CDC25C-luc (pAS2608) (kindly
provided by K. Engeland), pGL3-SM a-actin-Luc/
pAS2268 (containing the rat SM -actin promoter
sequences  713 to +51bp; kindly provided by S. Pham;
22), pAS2511, pAS2512 and pAS2513 (containing the
rat SM -actin promoter sequences  713 to +51bp
and mutations in either CArG box A, CArG box B or
both CArG boxes A and B, respectively), were made
by Quikchange mutagenesis using the primer-template
combinations ADS1617/ADS1618-pAS2268, ADS1619/
ADS1620-pAS2268, ADS1619/ADS1620-pAS2511,
respectively. pCGNSRF (encoding HA-tagged full-
length SRF, kindly provided by R. Prywes) was described
previously.
pAS2256 [encoding CMV-driven full-length His-Flag
tagged FOXK1(1–733)] was constructed by a two-step
procedure. First, the HindIII/XbaI fragment from
pAS1169 was cloned into the same sites in pCMV5
(encoding amino acids 97–733) to create pAS1173.
Next, a HindIII/AscI-cleaved PCR fragment (primer
pair ADS1315/ADS1316 and Image clone 30345138/
pAS1186 as a template) was ligated into the same
sites in pAS1173 to create pAS2256. pAS2265 [encoding
CMV-driven full-length His-Flag tagged FOXK1(1–733)
(H355A)] was constructed by ligating a KpnI/XbaI
fragment from pAS2259 into the same sites in pCMV5.
pAS1175 [encoding CMV-driven full-length His-Flag
tagged FOXM1b(1–763)] was constructed by ligating the
HindIII/XbaI fragment from pAS1171 into the same
sites in pCMV5. pAS2257 [encoding CMV-driven
FOXK1(1–262) fused to the GAL4 DNA-binding
domain] was constructed by ligating a BamHI/XbaI-
cleaved PCR fragment (primer pair ADS1315/ADS1297
and pAS2256 as a template) was ligated into the same sites
in pAS2063 (23).
For bacterial expression, pGEX-KG and pAS58
(encoding GST-core
SRF[amino acids 132–222]; 24) have
been described previously.
For in vitro transcription/translation, pAS1242
[encoding full-length Fkh2p(1–862)] has been described
previously (19). pAS2255 [encoding T3-driven full-length
His-Flag tagged FOXK1(1–733)] was constructed by a
two-step procedure. First, HindIII/XhoI-cleaved PCR
fragment (encoding amino acids 97–733; primer pair
ADS1168/ADS1169 and Image clone 5168241/pAS1184
as a template) was cloned into the same sites in pAS728
(25) to create pAS1169. Next, a HindIII/AscI-cleaved
PCR fragment (primer pair ADS1315/ADS1316 and
Image clone 30345138/pAS1186 as a template) was ligated
into the same sites in pAS1169 to create pAS2255.
pAS1168 [encoding T3-driven full-length His-Flag
tagged FOXK1(216–418)] was constructed by ligating a
NcoI/XhoI-cleaved PCR fragment (primer pair ADS1166/
ADS1167 and Image clone 5168241/pAS1184 as a
template) into the same sites in pAS728. pAS2259 and
pAS2258 [encoding T3-driven full-length His-Flag tagged
FOXK1(1–733)(H355A) and FOXK1(216–488)(H355A),
respectively] were created by QuikChange mutagenesis
using the primer pair ADS1342/ADS1343 on the tem-
plates pAS2255 and pAS1168, respectively. pAS1171
[encoding T3-driven full-length His-Flag-tagged
FOXM1b(1–748)] was constructed by ligating a HindIII/
XhoI-cleaved PCR fragment (primer pair ADS1177/
ADS1178 and Image clone 3834244/pAS1181 as a
template) into the same sites in pAS728.
Tissue culture, cell transfection, reporter geneassays,
RT-PCR and RNA interference
A total of 293 cells and muscle-derived RD18 rhabdo-
myosarcoma cells were grown in DMEM supplemented
with 10% foetal bovine serum. Transfections were
performed with Polyfect (Qiagen) for 293 cells or
Lipofectamine 2000 (Invitrogen) for RD18 cells according
to the manufacturer’s instructions.
For reporter gene assays, typically 0.25mg of reporter
plasmid and 50ng of pEF1/myc-His/LacZ or pCH110
were co-transfected with 0.005–2mg of expression plas-
mids. Cell extracts were prepared and equal amounts of
protein were used in luciferase and b-galactosidase assays
as described previously (26).
Real time RT-PCR was carried out as described
previously (27). The following primer-pairs were used
for RT-PCR experiments. FOXK1: ADS1372 (50-CGAGT
TCGAGTTCCTCATGC-30) and ADS1373 (50-GGGAG
ATCTGGGGGTACAGT-30), SM -actin: ADS1358 (50-
GCGTGGCTATTCCTTCGTTA-30) and ADS1359 (50-A
TGAAGGATGGCTGGAACAG-30), PPGB, ADS1348
(50-AGCTGCTTCCACCTACCTCA-30) and ADS1349
(50-CTTCTGGTTGAGGGAATCCA-30), SRF ADS1027
and ADS1028 (28), GAPDH, ADS4007 (50-ACAGTCAG
CCGCATCTTCTT-30) and ADS4008 (50-TTGATTTTG
GAGGGATCTCG-30) and18S internal control, ADS4005
(50-TCAAGAACGAAAGTCGGAGGTT-30) and
ADS4006, (50-GGACATCTAAGGGCATCACAG-30).
siRNA against FOXK1, and matched GAPDH control,
were constructed by the Silencer
TM siRNA construction
kit (Ambion). Human FOXK1 target sequences were:
FOXK1-1 50-TTGTGATAGAGCGACGTGACCTGTC
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GCGGTAACCCTGTCTC-30 (ADS1405/6) (italicized
residues represent sequences used in the in vitro transcrip-
tion process in producing the constructs). The siRNAs
against SRF and matched control siRNA (Santa Cruz)
were made synthetically. To carry out RNA interference
(RNAi), a two-step transfection protocol was carried out
in 12-well plates as described previously (27).
Western blot,co-immunoprecipitation andGST pulldown
analysis
Western blotting was carried out with the primary
antibodies; Flag (Sigma), GAPDH (Abcam), Erk2
(sc-154; Santa Cruz) and SRF (Santa Cruz) essentially
as described previously (27).
Coimmunoprecipitation analysis of overexpressed
proteins was performed using protein A sepharose beads
(Sigma) as described previously (29). GST pulldown
analysis was performed essentially as described previously
(24) with puriﬁed bacterially expressed recombinant
GST-core
SRF and in vitro translated FOXK1 derivatives.
GelretardationandinvitrobiotinylatedDNA-bindingassays
Gel retardation assays were performed as described pre-
viously using a fragment from the SWI5 promoter (4),
and core
SRF puriﬁed from bacteria (24) and in vitro
translated FOXK1 and Fkh2p derivatives.
The in vitro biotinylated DNA-binding assays were
performed essentially as described previously (30). Total
2 10
6 HEK293 cells were cotransfected with 8mg Flag
tagged FOXK1 plasmids and 200pmol control siRNA
or siSRF using lipofectamine 2000. Twenty-four hours
after transfection, the whole-cell extracts were incu-
bated with 1mg biotinylated Rat SM -actin promoter
DNA or 500pmol of CArG-A element, which were immo-
bilized on streptavidin–agarose beads (Dynabead M-280
streptavidin), in binding buﬀer [50mM HEPES KOH,
pH 7.9/150mM NaCl/0.5% Triton X-100/2mM EDTA/
20mM NaF/1mM Na3VO4/20mg/ml poly(dI-dC) and
protease inhibitors] at 48C for 60min. The beads were
washed four times with the binding buﬀer, and precipi-
tated proteins were analysed by western blotting. The
biotin-linked Rat -actin promoter was generated by PCR
using the template pAS2268 (for the wild-type promoter)
or pAS2513 (for the mutant promoter with both
CArG boxes disrupted and the primers ADS1692 (50-AA
GGGTCAGCGATAAACCAA-30) and ADS1693
(Biotin-CTTACCCTGATGGCGACTG-30). The biotin-
linked site containing CArG element A was created by
annealing the oligonucleotides ADS1694 (biotin-CCTG
TCTTTGCTCCTTGTTTGGGAAGCGAGTGGG) and
ADS1695 (CCCACTCGCTTCCCAAACAAGGAGCA
AAGACAGG).
ChIP assays
Chromatin immunoprecipitation (ChIP) assays using
control IgG (Upstate) or antisera speciﬁc to SRF (Santa
Cruz), E2A (Santa Cruz: E2A, E12 (V-18) SC-349) and
FOXK1 (Abcam) were performed as described previously
(31) except that cross-linking was performed for 10min.
Bound promoters were detected by PCR using primers
for the human SM -actin promoter (ADS1650, 50-CTCT
GGGCATTTCTGCAGTT-30 and ADS1651, 50-TTCTG
CTCTCCTCCCACTTG-30), the human PPGB promoter
(ADS1696, 50-ACTTAGCCGTCCACAACAGG-30 and
ADS1697 50-GGGGACTGGAAGTCATGTGT-30)o rf o r
the SRF promoter or intron 3 as described previously (28).
RESULTS
FOXK1 interacts withSRF in vivoand invitro
The Forkhead transcription factor Fkh2p interacts
with the MADS-box transcription factor Mcm1p in
S. cerevisiae. To establish whether a similar interaction
could be detected between the closest human homologue
of Mcm1p, SRF and a forkhead transcription factor, we
ﬁrst cloned the full-length human homologue of Foxk1/
MNF, by combining the sequences from two IMAGE
clones. The sequence we cloned was identical to that
recently identiﬁed by in silico approaches (32). Human
FOXK1 shares a conserved domain structure with
mouse Foxk1/MNF and yeast Fkh2p, with an FHA
domain preceding the Forkhead DNA-binding domain
(Figure 1A). Overall, there is 90% sequence identity
between human and mouse FOXK1/Foxk1. The sequence
conservation between human FOXK1 and yeast Fkh2p is
substantially lower (20% identity) and is concentrated
mainly in the FHA and Forkhead domains.
Next, we co-expressed epitope-tagged versions
of FOXK1 and SRF in human 293 cells and carried
out co-immunoprecipitation analysis. Co-precipitation of
SRF and FOXK1 was observed which was dependent on
the expression of both transcription factors (Figure 1B).
To establish whether endogenous SRF could interact with
FOXK1, we expressed Flag epitope-tagged FOXK1 and
attempted to co-precipitate SRF. Endogenous SRF was
co-precipitated with FOXK1 (Figure 1C). We were
however unable to detect interactions between SRF and
FOXK1 expressed at endogenous levels, most likely due
to the low levels of expression of these proteins coupled
with the likely substoichiometric association of these
transcription factors (data not shown). Interactions
between yeast Fkh2p and Mcm1p occur with the DNA-
binding domain of Mcm1p. We therefore tested whether
we could detect analogous interactions between FOXK1
and SRF in vitro. Indeed, the DNA-binding domain of
SRF (core
SRF) was suﬃcient for interaction with FOXK1
in a GST pulldown assay (Figure 1D). This interaction
was speciﬁc as diﬀerent forkhead proteins FOXM1b and
FOXN3 were unable to form speciﬁc complexes with
core
SRF (data not shown). Moreover, both FOXK1 and
Fkh2p could form complexes with SRF on a fragment
derived from the SWI5 promoter (Figure 1E), a known
binding site for the Fkh2p-Mcm1p complex, which
contains a composite binding motif for both SRF and
the forkhead transcription factor (2–4). In contrast,
FOXM1b was unable to form a similar complex (data
not shown).
Collectively, these data demonstrate that in common
with their yeast counterparts the human Forkhead
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interact in vivo and in vitro.
FOXK1 isarepressor and inhibitsSRF-dependent
promoter activity
A short splice form of the mouse homologue of FOXK1,
MNFb has previously been shown to act as a transcrip-
tional repressor (15). Full-length FOXK1 acts as a potent
repressor of a reporter gene controlled by multimerized
forkhead binding sites (Figure 2A). In contrast,
FOXM1b acts as a transcriptional activator in this assay
(Figure 2A). The N-terminal part of FOXK1 which
includes the FHA domain is suﬃcient to repress transcrip-
tion, as revealed by the ability of a GAL-FOXK1(1–262)
fusion protein to repress transcription (Figure 2B).
This eﬀect is speciﬁc, as the GAL4 DNA-binding
domain alone or other control GAL4 fusions do not
cause such dose-dependent decreases in reporter activity
(data not shown).
To establish potential functional interactions with SRF,
we examined the activity of FOXK1 on a reporter driven
by multimerized SRF binding sites (CArG-luc). FOXK1
functioned as repressor of this reporter gene while the
alternative forkhead transcription factor FOXM1b had
little eﬀect on the activity of this reporter (Figure 2C).
Importantly, upon depletion of SRF by siRNA, the
repressive eﬀect of FOXK1 on the CArG-luc reporter was
lost (Figure 2D). Thus, FOXK1 can repress SRF-
dependent promoter activation.
FOXK1 andSRF coregulate the expression of SMa-actin
A previous microarray study has identiﬁed a number of
potential FOXK1 target genes through the analysis of
muscle side population cells derived from foxk1/mnf
knockout mice (33). Similarly, a number of SRF target
genes were identiﬁed through microarray analysis fol-
lowing the expression of SRF-VP16 fusion proteins in ES
cells derived from srf knockout mice (34). Two of the
deregulated genes in both cases were smooth muscle (SM)
-actin and PPGB (encoding a lysosomal protective pro-
tein) which were induced by either loss of Foxk1/MNF or
expression of SRF-VP16, making this a likely candidate
for detecting functional interactions between these two
transcription factors.
First, we conﬁrmed the involvement of human FOXK1
and SRF in controlling SM -actin and PPGB expression.
Two diﬀerent siRNAs were derived which caused the
depletion of FOXK1 expression at both the protein and
RNA levels (Figure 3A and B). Upon depletion of FOXK1
in 293 cells, we observed a large increase in SM -actin
and PPGB levels with both siRNA constructs, consistent
with a role for FOXK1 in repressing the activity of these
genes (Figure 3B). Similar results were obtained in muscle-
derived RD18 rhabdomyosarcoma cells (data not shown).
Conversely, the depletion of SRF caused a substantial
decrease in the expression of SM -actin and PPGB
expression (Figure 3C), conﬁrming the ability of SRF to
activate the expression of these genes. Indeed, other
studies have previously also implicated SRF in controlling
the activity of SM -actin (35). Importantly, ChIP analysis
demonstrated that both FOXK1 and SRF could be found
associated with the endogenous SM -actin and PPGB
genes in 293 (Figure 3E) and RD18 cells (data not shown).
In contrast, only SRF was found to associate with the srf
promoter and neither protein associated with an intron
found in the srf gene (Figure 3E, bottom panels). Thus,
both FOXK1 and SRF can directly associate with
the promoter regions and control the expression of SM
-actin and PPGB.
To establish whether FOXK1 could aﬀect the activity of
the SM -actin promoter, we carried out reporter gene
assays. Overexpression of FOXK1 caused the dose-
dependent repression of a SM -actin promoter–reporter
construct (Figure 4A). In contrast, at the same levels of
expression, little eﬀect was observed on the activity of
a CDC25C promoter–reporter construct (Figure 4B).
Conversely, knockdown of FOXK1 expression caused an
Figure 1. FOXK1 and SRF interact in vivo and in vitro.( A) Schematic
of the domain structure of Foxk1 and Fkh2p. (B) Co-immunoprecip-
itation of FOXK1 with SRF from 293 cells transfected with constructs
encoding Flag-FOXK1 and/or HA-SRF where indicated. FOXK1
proteins were immunoprecipitated by Flag antibody, and precipitated
proteins detected by immunoblotting (IB) using SRF or Flag
(for FOXK1) antibodies. (C) Co-immunoprecipitation of FOXK1
with endogenous SRF from 293 cells transfected with a construct
encoding Flag-FOXK1. FOXK1 proteins were immunoprecipitated by
Flag antibody, and precipitated proteins detected by immunoblotting
(IB) using SRF or Flag (for FOXK1) antibodies. (D) GST pull-down
analysis of FOXK1 interaction with SRF. GST-core
SRF or GST alone
was used in a GST pull-down assay with full-length in vitro translated
FOXK1. (E) Gel retardation analysis of the binding of core
SRF,
FOXK1 and Fkh2p (where indicated) to a fragment of the SWI5
promoter. The locations of complexes formed with core
SRF alone and
binary FOXK1-SWI5 (28) or ternary FOXK1-core
SRF-SWI5 (38) are
indicated by arrows. Asterisks represents non-speciﬁc bands arising
from the reticulocyte lysate.
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(Figure 4C). This eﬀect was speciﬁc, as no eﬀect was seen
on the CDC25C promoter (Figure 4D). Thus, FOXK1
acts to repress the activity of the SM -actin promoter.
FOXK1 regulates SMa-actin expression in aDNA-binding
independent manner
FOXK1 might regulate the SM -actin promoter through
either direct promoter binding or indirectly through asso-
ciation with SRF. We therefore created a mutant form of
FOXK1 containing a point mutation in a region that is
predicted to disrupt its DNA-binding surface [FOXK1
(H355A)]. This point mutation did not aﬀect interactions
between FOXK1 and SRF (Figure 5A), but severely
compromised the ability of FOXK1 to bind to DNA
(Figure 5B, lanes 7–9). Indeed, FOXK1(H355A) exhibited
much reduced repressive ability on a reporter driven by six
forkhead binding sites (6xFox-luc; Figure 5C).
Next, we demonstrated that increasing amounts of
SRF were able to activate the SM -actin promoter in
293 cells (Figure 5D). Conversely, when we co-expressed
increasing amounts of wild-type FOXK1 with SRF, we
were able to demonstrate that FOXK1 was able to repress
the activity of this SRF-activated reporter in this cell type
(Figure 5E). Moreover, the DNA-binding defective
FOXK1(H355A) also repressed the activity of the SM
-actin promoter to a similar extent as the wild-type
protein (Figure 5E) suggesting that FOXK1 does not need
to bind to DNA directly. Indeed, in agreement with this,
we were unable to detect signiﬁcant binding of wild-type
FOXK1 to fragments of the SM -actin promoter in vitro
(data not shown). Similarly, both wild-type FOXK1 and
FOXK1(H355A) were able to repress the SM -actin
promoter in the presence of endogenous levels of SRF in
RD18 cells (Figure 5F).
Together these data demonstrate that FOXK1 can
regulate the SM -actin promoter in a DNA-binding
independent manner.
FOXK1 regulates the expression of SMa-actinthrough SRF
A likely mechanism through which FOXK1 regulates the
SM -actin promoter is via direct interactions with SRF.
To establish whether this is the case, we ﬁrst carried out
Figure 2. FOXK1 represses SRF-dependent promoter–reporter activity.
(A–D) Luciferase reporter assays with the indicated promoter–reporter
plasmids (shown schematically at top of each graph). (A) A 6xFox-Luc
reporter construct (250ng) was transfected in the presence of increasing
amounts of Flag-tagged FOXK1 (0, 100, 200 and 400ng) or FOXM1b
(0, 200, 400 and 800ng) expression constructs in 293 cells. (B) A Lex-
GAL-Luc reporter construct (250ng) was transfected in the presence
and absence of Lex-VP16 (100ng) and increasing amounts of GAL-
FOXK1(1–262) (0, 5, 10, 50 and 100ng) constructs in 293 cells. (C) A
5xCArG-Luc reporter construct (250ng) was transfected in the presence
of increasing amounts of Flag-tagged FOXK1 (0, 100, 200 and 400ng)
or FOXM1b (0, 200, 400 and 800ng) expression constructs in 293 cells.
Data in A–C are presented relative to the activity of the reporter in the
absence of FOXK1/FOXM1b (taken as 100%) and are the average of
triplicate samples. (D) A 5xCArG-Luc reporter construct (250ng) was
transfected in the presence and absence of a Flag-tagged FOXK1
expression construct (100ng) in 293 cells. siRNA duplexes against
GAPDH or SRF were cotransfected where indicated. Data are the
average of triplicate samples.
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reporter constructs in which either one or both of the two
SRF binding sites were mutated (Figure 6A). FOXK1 was
able to repress the activity of the wild-type promoter, but
this activity was reduced upon mutation of either of the
two SRF binding sites. Moreover, the repressive activity
of FOXK1 was virtually abolished upon mutation of
both SRF binding sites (CArG-A/Bmut; Figure 6A).
Next, we depleted endogenous SRF levels by siRNA
treatment (Figure 6B). Upon depletion of SRF, the ability
of FOXK1 to repress the SM -actin promoter was
blunted.
Finally, we asked whether SRF was required for
FOXK1 recruitment to the SM -actin promoter.
We were unable to detect FOXK1 binding to the SM
-actin promoter by gel retardation analysis (data not
shown), therefore, we used an immobilized biotinylated-
DNA-binding assay to detect FOXK1-DNA interactions
in vitro. Either the wild type or a mutant version
(with both CArG boxes disrupted) of the SM -actin
promoter were coupled to streptavidin-linked beads.
As a further control, we created duplexes which spanned
just the proximal CArG (CArG-A) from this promoter.
Extracts from 293 cells were used in the binding assays
from cells that had been transfected with Flag-tagged
FOXK1 in the presence of control siRNA or siRNA
constructs against SRF. Binding of FOXK1 to the wild-
type SM -actin promoter could be detected and this
binding was reduced upon depletion of SRF (Figure 7A,
lanes 5 and 6). Similar eﬀects were seen on the isolated
Figure 3. FOXK1 and SRF control SM -actin expression.
(A) Western analysis of the expression of Flag-tagged FOXK1
expression in 293 cells cotransfected with siRNA duplexes against
GAPDH or FOXK1 where indicated. (B–C) Real time RT-PCR analysis
of the expression of the indicated genes in 293 cells transfected with,
(B) RNAi duplexes against GAPDH or FOXK1, or (C) and RNAi
duplex against SRF or a control duplex. Data are representative of 2–3
independent experiments and the average of triplicate samples.
(D) ChIP analysis using the indicated antibodies in 293 cells.
Coprecipitating SM -actin promoter, PPGB promoter, SRF promoter
or SRF intron 3 was detected by PCR.
Figure 4. FOXK1 represses SM -actin promoter activity. (A and B)
Luciferase reporter assays with the SM -actin (A) or CDC25C
(B) promoter–reporter plasmid (250ng) (shown schematically at top of
each graph). RD18 cells were cotransfected with increasing amounts of
FOXK1 expression construct (0, 50, 100, 200 and 400ng). Western
blots of FOXK1 and Erk2 (control) expression are shown below each
graph. (C and D) Luciferase reporter assays with the SM -actin (C) or
CDC25C (D) promoter–reporter plasmid (250ng) (shown schematically
at top of each graph). Total 293 cells were cotransfected with increasing
amounts of FOXK1 expression construct (0, 50, 100, 200 and 400ng).
Data are presented relative to reporter alone (taken as 1) and are the
average of triplicate samples.
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reductions in binding mirrored the reductions in SRF
binding. In comparison to the wild-type promoter, the
mutant SM -actin promoter showed reduced levels of
both SRF and FOXK1 binding (Figure 7A, lanes 7 and 8).
Thus, SRF is required for eﬃcient recruitment of FOXK1
to the SM -actin promoter.
To establish whether the same mechanism is operative
in vivo, ChIP analysis was used to monitor the occupancy
of the SM -actin promoter upon SRF depletion. The
reduction of SRF levels caused the expected reduction of
SRF binding to the SM -actin promoter. However, the
binding of FOXK1 was also compromised (Figure 7B, top
two panels). This reduction was not due to a general
eﬀect on SM -actin promoter occupancy as the binding
of an alternative transcription factor E2A (36) was main-
tained upon SRF depletion. Similar results were obtained
on the PPGB promoter, where SRF depletion led to
reductions in both SRF and FOXK1 binding (Figure 7B,
panels 3 and 4).
Together these results therefore demonstrate that SRF
is required for the FOXK1 to regulate and be recruited
to the SM -actin promoter. Thus, FOXK1 and SRF
interact both physically and functionally to control the
activity of target genes such as SM -actin and PPGB.
DISCUSSION
Complexes between Forkhead and MADS-box transcrip-
tion factors have previously been shown to be an
important common combination involved in controlling
the cyclical expression of cell cycle genes in S. cerevisiae.
Here, we demonstrate that this combination of transcrip-
tion factors is also functionally important in human
cells, adding to the repertoire of transcription factor
modules that function in metazoan systems. Speciﬁcally,
Figure 5. FOXK1 represses SM -actin expression in a DNA-binding independent manner. (A) GST pull-down analysis of GST-core
SRF or GST
with full-length in vitro translated wild-type (WT) FOXK1 or FOXK1(H355A). (B) Gel retardation analysis of the binding of either core
SRF,o r
truncated versions (amino acids 216–488) of FOXK1(WT) and FOXK1(H355A) (where indicated) to a fragment of the SWI5 promoter.
The locations of complexes formed with core
SRF alone and binary FOXK1-SWI5 (28) or ternary FOXK1-core
SRF-SWI5 (38) are indicated by arrows.
Anti-Flag antibody is added where indicated to demonstrate the presence of FOXK1 in the complexes. (C–F) Luciferase reporter assays with the
6xFox site (C) or SM -actin promoter–reporter plasmid (D–F) (250ng) (shown schematically at top of each graph). (C) 293 cells were transfected
increasing amounts (0, 100, 200 and 400ng) of wild-type (WT) or H355A mutant FOXK1 expression constructs. (D) 293 cells were transfected with
increasing amounts of SRF expression construct (0, 1, 5, 10, 20 and 50ng). A western blot of SRF expression is shown below. Data are presented
relative to reporter alone and are the average of triplicate samples. (E and F) 293 (E) or RD18 (F) cells were transfected increasing amounts (0, 100,
200 and 400ng) of wild-type (WT) or H355A mutant FOXK1 expression constructs. Cells were also cotransfected with an SRF expression construct
(20ng) in (E). Western blots of FOXK1 expression in cells transfected with 200ng expression construct are shown as insets. Data are presented
relative to the activity of the reporter in the absence of FOXK1 (taken as 100%) and are the average of triplicate samples.
Nucleic Acids Research, 2007, Vol. 35, No. 15 5209we demonstrate that the human Forkhead transcription
factor FOXK1 functionally interacts with the MADS-box
protein SRF.
FOXK1 can form complexes with SRF in the absence
of DNA through binding to the minimal core DNA-
binding domain of SRF which includes the MADS-box
(Figure 1). Indeed, a mutant form of FOXK1 that cannot
bind to DNA eﬃciently can still control SRF-dependent
promoter activity in vivo (Figure 5). However, SRF is
required for the eﬃcient recruitment of FOXK1 to target
promoters in vitro and in vivo (Figures 2 and 7). This
suggests a model whereby SRF acts as a platform to
recruit FOXK1 (Figure 7C). FOXK1 can then repress
promoter activity. These observations are fully consistent
with the known roles of SRF and other MADS-box
proteins in acting as a platform for the assembly of many
diﬀerent types of transcriptional regulatory complexes,
some of which like MRTFs make minimal DNA interac-
tions (7,37).
The paradigm for interactions between Forkhead
and MADS-box transcription factors is the yeast
Fkh2p-Mcm1p complex (2–5). However, while there are
important overall similarities between the Fkh2p-Mcm1p
and human FOXK1-SRF complexes, their modes of
interaction and regulation are not identical. Both Fkh2p
and FOXK1 share a similar domain structure, with both
possessing an N-terminally located FHA domain in addi-
tion to the Forkhead DNA-binding domain. FOXK1
is a transcriptional repressor protein, and Fkh2p can also
repress transcription of its target genes during the early
Figure 6. FOXK1 represses SM -actin expression in a SRF-dependent
manner. (A) Luciferase reporter assay with the indicated wild-type
(WT) and mutant SM -actin promoter–reporter plasmids (250ng)
(shown schematically at top of ﬁgure). Total 293 cells were transfected
with each reporter in the absence and presence of a FOXK1 expression
construct (200ng). (B) Luciferase reporter assay in 293 cells transfected
with the wild-type (WT) SM -actin promoter–reporter plasmid
(250ng) in the absence and presence of a FOXK1 expression construct
(200ng) and either control siRNA duplexes or siRNA duplexes against
SRF. A western blot showing the expression of FOXK1, SRF and
GAPDH expression are shown below the graph. Data in A and B are
presented relative to the activity of cotransfected pCH110 and are the
average of triplicate samples.
Figure 7. FOXK1 binds to the SM -actin expression in a SRF-
dependent manner. (A) In vitro biotinylated DNA-binding assay.
Binding to the indicated DNA fragments of proteins from extracts of
293 cells transfected with a FOXK1 expression vector and siRNAs
against SRF where indicated. Input proteins and proteins remaining
bound to the DNA after washing were detected by immunoblotting
(IB) with the indicated antibodies. The SM-act fragments contain
743bp of the SM -actin promoter surrounding either the intact WT or
mutated (mut) CArG boxes. The CArG-A site contains only
CArG box A. Quantiﬁcation of FOXK1 binding in two independent
experiments is shown graphically below the ﬁgure. (B) ChIP analysis
using an IgG control or antibodies against FOXK1, SRF or E2A
antibody in 293 cells. Cells were transfected with either a control
siRNA duplex (cont) or a siRNA against SRF. Precipitated SM -actin
promoter was detected by PCR. (C) Model for how FOXK1 controls
the activity of SRF target genes through SRF-dependent recruitment,
and subsequent transcriptional repression.
5210 Nucleic Acids Research, 2007, Vol. 35, No. 15part of the cell cycle (3–5). The mouse homologue of
FOXK1, Foxk1/MNFb represses transcription through
the recruitment of the Sin3 corepressor (38) and Fkh2p
can also bind to Sin3 in vitro (our unpublished data).
In contrast, to date, no transcriptional activation capac-
ity has been identiﬁed for mammalian FOXK1 proteins,
and the region encompassing the FHA domain has
repressive activity rather than the transactivation ability
exhibited by the same region in Fkh2p (Figure 2;
12,13,38). Moreover, to date, we have been unable to
establish a role for the FOXK1-SRF complex in cell cycle
control (our unpublished data), and instead, an alternative
forkhead protein FOXM1 appears to perform the major
role in controlling G2-M phase transcription in mamma-
lian cells (18). Our data indicate that FOXM1 does not
function through binding and changing the activity
of SRF (Figure 2, data not shown).
There also seem to be important diﬀerences between
human and mouse FOXK1 proteins. In mice, there
are two isoforms of Foxk1/MNF, MNFa and the
shorter splice form MNFb. However, only the latter
apparently shows DNA-binding and transcriptional reg-
ulatory capacity (15). In contrast, full-length human
FOXK1 (equivalent to MNFa) can bind to DNA and
regulate transcription (Figures 1 and 2). Secondly, muta-
tions designed to disrupt the phosphopeptide binding
activity of the FHA domain of MNFb partially dimin-
ished the repressive activity of MNFb (15) but were
without eﬀect in FOXK1 (data not shown). It is currently
unclear why these proteins apparently function diﬀerently
but these observations might reﬂect important evolution-
ary diﬀerences.
To establish the importance of the FOXK1-SRF
interaction, we demonstrated that this complex functions
on the SM -actin and PPGB genes, and that FOXK1 has
a repressive role in the complex. However, FOXK1 does
not seem to be an obligate partner for SRF as we could
not detect FOXK1 binding to the diﬀerent target gene,
SRF (Figure 3). Thus, FOXK1 is likely to be a sub-
stoichimetric partner for SRF, as suggested by our
inability to co-immunoprecipitate endogenous FOXK1
and SRF. Biologically, FOXK1 is likely to restrict the
expression of SM -actin expression in non-smooth
muscle cell types such as the stem cell-like myogenic side
population cells (33). Recently, another forkhead tran-
scription factor Foxo4 was shown to repress SM -actin
expression in proliferating smooth muscle cells (39).
In common with FOXK1, Foxo4 repressed transcription
in a DNA-binding independent manner and achieved
this through interacting with and inhibiting the
SRF-myocardin activator complex. Direct interactions
between Foxo4 with SRF were not however shown. A
diﬀerent SRF partner protein Elk-1 was also shown to
inhibit the expression of a number of smooth muscle-
speciﬁc genes (40). However, Elk-1 is ineﬀective against
SM -actin. Thus, several diﬀerent ways might have been
devised to reduce the expression of diﬀerent smooth
muscle genes in diﬀerent cell types through impacting on
the activity of SRF.
In summary, we have identiﬁed a novel combination
of functionally interacting human transcription factors,
the Forkhead protein FOXK1 and MADS-box protein,
SRF. Future studies will focus on how common this mode
of SRF target gene regulation is in human cells.
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